Absci Corporation (Nasdaq: ABSI) announces a $75 million public offering to support internal drug development, enhance their Integrated Drug Creation™ platform, and serve general corporate purposes. The offering includes an option for an additional $11.25 million. Morgan Stanley and TD Cowen will act as joint book-running managers. Funds will expedite therapeutic solutions, innovate drug discovery, and fuel long-term growth.
Absci Corporation (Nasdaq: ABSI), a pioneer in leveraging generative AI for drug discovery, has announced its intention to initiate a public offering of $75 million in common stock. This move is aimed at bolstering Absci’s internal drug development initiatives, furthering investment in their groundbreaking Integrated Drug Creation™ platform, and serving general corporate objectives.
Offering Specifics
The offering entails Absci’s plan to offer $75 million worth of common stock, with an option for an additional $11.25 million to be sold at the underwriter’s discretion. The final terms of the offering will be contingent upon market conditions and other relevant factors, to be disclosed in a subsequent prospectus supplement. Morgan Stanley and TD Cowen have been appointed as joint book-running managers for the offering.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Utilization of Funds for Growth and Innovation
Absci intends to allocate the net proceeds from the offering towards various strategic initiatives:
– Advancement of internal drug development programs: This allocation will expedite the delivery of novel therapeutic solutions to patients.
– Enhancement of the Integrated Drug Creation™ platform: By integrating AI with wet lab technology, Absci aims to streamline the drug discovery and development process.
– Support for ongoing operations and future endeavors: The capital raised will underpin general corporate functions and drive Absci’s long-term growth trajectory.
